Mitral regurgitation is the second most frequent heart valve disease in Europe and the most frequent in the US. Although surgery is the therapy of choice when intervention is indicated, transcatheter mitral valve repair or replacement are alternatives for patients who are not eligible for surgery. However, the development of transcatheter mitral valves is slower than expected. Although several transcatheter heart valves have been developed, only one has been commercialised. Indeed, most of these devices are being evaluated in clinical studies, with promising initial results. In this review, we propose an overview on transcatheter mitral valve replacement for the treatment of native mitral valve disease, from indication to results, including patients with severe annular calcification, and we provide you with a glimpse into the future of these therapies.

中文翻译：

---

经导管二尖瓣植入术治疗自体瓣膜疾病。

二尖瓣关闭不全是欧洲第二常见的心脏瓣膜疾病，也是美国最常见的心脏瓣膜疾病。尽管手术是需要干预时的首选治疗方法，但经导管二尖瓣修复或置换是不适合手术的患者的替代方案。然而，经导管二尖瓣的发展比预期要慢。尽管已经开发出多种经导管心脏瓣膜，但只有一种已商业化。事实上，大多数这些设备正在临床研究中进行评估，并取得了有希望的初步结果。在这篇综述中，我们对经导管二尖瓣置换术治疗自体二尖瓣疾病从适应症到结果进行了概述，包括患有严重瓣环钙化的患者，并让您一睹这些疗法的未来。